Hypoxia is a common feature of solid tumors, and develops because of the rapid growth of
the tumor that outstrips the oxygen supply, and impaired blood flow due to the formation of …

Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of
cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75–85 …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Solid tumours contain regions at very low oxygen concentrations (hypoxia), often
surrounding areas of necrosis. The cells in these hypoxic regions are resistant to both …

Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …

Hypoxia-inducible factors (HIFs) mediate adaptive physiological responses to hypoxia. In
human cancers that are accessible for O 2 electrode measurements, intratumoral hypoxia is …

It is well established that multifactorial drug resistance hinders successful cancer treatment.
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …

Hypoxia, a hallmark of solid tumors, determines the selection of invasive and aggressive
malignant clones displaying resistance to radiotherapy, conventional chemotherapy or …

Resistance of human tumors to anticancer drugs is most often ascribed to gene mutations,
gene amplification, or epigenetic changes that influence the uptake, metabolism, or export of …

Anthracyclines have been important and effective treatments against a number of cancers
since their discovery. However, their use in therapy has been complicated by severe side …